In Vitro Fertilization Pregnancy Outcomes and Effect of Atosiban Among Women With Endometriosis in Presence or Absence of Adenomyosis

Chih‐Wei Lin, Meng-Hsing Wu, Yu‐Lin Mau, Pei‐Fang Su, Huang‐Tz Ou
In: Research Square · 2021 · doi:10.21203/rs.3.rs-963721/v1 · W3206320893
preprint OA: green CC0
📄 Open PDF View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

This study found lower IVF pregnancy and live birth rates in women with both endometriosis and adenomyosis compared to those with only endometriosis, and atosiban improved pregnancy in the latter group but not significantly in the former.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-09 ⓘ

This retrospective cohort study evaluated IVF pregnancy outcomes and the effect of atosiban (an oxytocin receptor antagonist given before and after embryo transfer) in 34 women with both endometriosis and adenomyosis (66 ET cycles) compared with 34 women with endometriosis without adenomyosis (54 ET cycles) and 38 women with tubal factor infertility (56 ET cycles), using multivariable logistic generalized estimating equation models adjusting for maternal and treatment characteristics. Women with endometriosis-only had significantly higher biochemical pregnancy and live birth rates than those with concurrent endometriosis and adenomyosis (ORs 2.981 and 2.694, respectively), while tubal-only did not differ significantly from endometriosis+adenomyosis. Within endometriosis-only patients, atosiban use was positively associated with biochemical pregnancy, but no significant benefit was observed in the endometriosis+adenomyosis group overall, and atosiban-related increases were not significant across pregnancy endpoints, including in extensive adenomyosis. The paper explicitly notes limitations of its retrospective design and preprint status (not peer reviewed). This paper is centrally about endometriosis—specifically testing how atosiban’s IVF pregnancy effects differ when adenomyosis co-occurs.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Abstract BackgroundThe use of atosiban during embryo transfer (ET), an oxytocin receptor antagonist, has been demonstrated to enhance pregnancy rate among infertile patients with endometriosis. However, its efficacy has not been assessed among those with concurrent adenomyosis, which may further affect pregnancy rate.MethodsThis retrospective cohort study assessed in vitro fertilization (IVF) pregnancy, and the effect of atosiban among 34 women with both endometriosis and adenomyosis (with 66 ET cycles), compared to 34 endometriosis patients without adenomyosis (with 54 ETs) and 38 patients with tubal factor (with 56 ETs). Multivariable logistic generalized estimating equation analyses were performed to assess pregnancy outcomes with adjustment for maternal and treatment characteristics.ResultsSignificantly higher chances of biochemical pregnancy and live birth among endometriosis patients without adenomyosis versus those with both endometriosis and adenomyosis were found (odds ratios [95% confidence intervals]: 2.981 [1.307, 6.803]; p =0.009, 2.694 [1.151, 6.304]; p =0.022). A significant positive association between atosiban use and biochemical pregnancy existed among endometriosis cases without adenomyosis (a 2.43-fold [1.01, 5.89] increase in successful pregnancy; p <0.05), but not for the other groups. An insignificant increase in pregnancy rates was found for atosiban-treated extensive adenomyosis cases (i.e., ≥50%) versus non-treated cases (biochemical pregnancy, ongoing pregnancy, and live birth: 42.9% versus 33.3%, 37.5% versus 14.3%, and 25.0% versus 14.3%, respectively).ConclusionsPoor pregnancy outcomes among adenomyosis-affected women were confirmed. The use of atosiban significantly enhanced IVF pregnancy among endometriosis patients without adenomyosis. Atosiban use might benefit those with more extensive adenomyosis.

My notes (saved in your browser only)

Condition tags

endometriosisadenomyosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (15)

Source provenance

europepmc
last seen: 2026-06-12T06:25:08.868844+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK